アルツハイマー病の治療法

Nick C Fox¹, Christopher Belder², Clive Ballard³

¹Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute at UCL, University College London, London, UK.

Lancet (London, England)

|September 25, 2025

まとめ

この研究は,患者の生活の質を改善するために,アミロイド抗単体抗体を含む既存の治療法と新しい治療法を用いて,アルツハイマー病の症状を管理するための実用的なガイドラインを提供します.

科学分野:

神経科学
高齢者医療
薬理学について

背景:

アルツハイマー病 (AD) の治療法に関する証拠は 30年以上にわたって増えています
現在の薬理学的および非薬理学的戦略は,限られた厳格な有効性の証拠を示しています.
新しい治療法と既存の治療を統合することは臨床的な課題です

研究の目的:

認知症と非認知症の治療の優先順位について実践的なアドバイスを提供すること.
アンチアミロイド単体抗体の認知症治療への統合について議論する.
モノクローナル抗体の患者の生活の質を改善する可能性を評価する.

主な方法:

アルツハイマー病の管理戦略に関する現在の証拠のレビュー
抗アミロイド単体抗体の承認状況と臨床統合の分析
整体的な患者ケアのための勧告のまとめ

主要な成果:

アルツハイマー病の症状に対する既存の治療法は有効性には限界があります
抗アミロイド単体抗体はアルツハイマー病の治療における新しい境界線を象徴しています
新しい治療法と既知の治療法を円滑に統合することが重要です

結論:

アルツハイマー病の管理には根拠に基づいた戦略を優先することが重要です
抗アミロイドモノクローナル抗体は患者の生活の質に潜在的な利点をもたらします.
最適なアルツハイマー病の治療には,新しい治療法と既存の治療法を統合した総合的なアプローチが推奨されています.

さらに関連する動画

05:54

Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials

Published on: May 10, 2024

2.0K

08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

12.5K

関連する概念動画

01:22

Alzheimer's Disease: Treatment

824

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

824

01:26

Alzheimer's Disease: Overview

1.6K

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

1.6K

01:24

Parkinson's Disease: Treatment

986

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

986

01:30

Dementia

523

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....

523

01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

560

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

560

01:15

Parkinson's Disease: Overview

1.8K

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...